Immunovant (IMVT) director Fromkin sells 221,951 shares after exercising options

Rhea-AI Filing Summary

Immunovant, Inc. director Andrew J. Fromkin reported a combination of option exercises and share sales in common stock. On May 28, 2026, he exercised stock options covering 196,601 shares at strike prices ranging from $4.99 to $14.70 per share, converting derivative awards into common shares.

On the same date, he executed open-market sales totaling 221,951 shares of common stock at weighted average prices of $33.56 and $32.64 per share across multiple trades. Following these transactions, he directly holds 74,382 Immunovant common shares, indicating a net reduction in his direct equity position while retaining a meaningful stake.

Insights

Insider trading analyst

Director exercised options then sold more shares than acquired, a routine net-sell pattern.

Director Andrew J. Fromkin exercised stock options for 196,601 Immunovant shares at strike prices between $4.99 and $14.70. This converts previously granted derivative awards into common stock, a typical compensation-related event when options are fully vested.

He also executed open-market sales totaling 221,951 shares at weighted average prices of $32.64 and $33.56. After these trades, he directly holds 74,382 shares, so his position decreased but remains sizable. With no remaining options shown in this filing and no 10b5-1 trading plan disclosure in the excerpt, this looks like a discretionary portfolio move rather than a structural change to the company.

Insider Trade Summary

Net Seller: 221,951 shares ($7,438,111)

Net Sell 10 txns

Insider Fromkin Andrew J.

Role null

Sold 221,951 shs ($7.44M)

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	31,668	$0.00	--
Exercise	Stock Option (right to buy)	71,492	$0.00	--
Exercise	Stock Option (right to buy)	77,181	$0.00	--
Exercise	Stock Option (right to buy)	16,260	$0.00	--
Exercise	Common Stock	31,668	$4.99	$158K
Exercise	Common Stock	71,492	$7.94	$568K
Exercise	Common Stock	77,181	$8.43	$651K
Exercise	Common Stock	16,260	$14.70	$239K
Sale	Common Stock	11,483	$32.64	$375K
Sale	Common Stock	210,468	$33.56	$7.06M

Holdings After Transaction: Stock Option (right to buy) — 0 shares (Direct, null); Common Stock — 131,400 shares (Direct, null)

Footnotes (1)

1. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.04 - $33.035 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.04 - $33.85 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Reflects an award of stock options to purchase Common Shares that is fully vested.

Key Figures

Shares sold: 221,951 shares Sale price (block 1): $33.56 per share Sale price (block 2): $32.64 per share +5 more

8 metrics

Shares sold 221,951 shares Open-market sales on May 28, 2026

Sale price (block 1) $33.56 per share Weighted average price for 210,468 shares sold

Sale price (block 2) $32.64 per share Weighted average price for 11,483 shares sold

Options exercised 196,601 shares Stock option exercises on May 28, 2026

Strike price tier 1 $14.70 per share Exercise price for 16,260 options

Strike price tier 2 $8.43 per share Exercise price for 77,181 options

Strike price tier 3 $7.94 per share Exercise price for 71,492 options

Strike price tier 4 $4.99 per share Exercise price for 31,668 options

Key Terms

open-market sale, Stock Option (right to buy, weighted average price, Exercise or conversion of derivative security

4 terms

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Stock Option (right to buy financial

"security_title": "Stock Option (right to buy)""

weighted average price financial

"The price reported is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Exercise or conversion of derivative security financial

"transaction_code_description": "Exercise or conversion of derivative security""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fromkin Andrew J.

(Last) (First) (Middle)

C/O IMMUNOVANT, INC.

1000 PARK FORTY PLAZA, SUITE 210

(Street)

DURHAM NORTH CAROLINA 27713

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Immunovant, Inc. [ IMVT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/28/2026		M		31,668	A	$4.99	131,400	D
Common Stock	05/28/2026		M		71,492	A	$7.94	202,892	D
Common Stock	05/28/2026		M		77,181	A	$8.43	280,073	D
Common Stock	05/28/2026		M		16,260	A	$14.7	296,333	D
Common Stock	05/28/2026		S		11,483	D	$32.64(1)	284,850	D
Common Stock	05/28/2026		S		210,468	D	$33.56(2)	74,382	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$4.99	05/28/2026		M			31,668	(3)	08/17/2032	Common Stock	31,668	$0	0	D
Stock Option (right to buy)	$7.94	05/28/2026		M			71,492	(3)	01/10/2032	Common Stock	71,492	$0	0	D
Stock Option (right to buy)	$8.43	05/28/2026		M			77,181	(3)	11/19/2029	Common Stock	77,181	$0	0	D
Stock Option (right to buy)	$14.7	05/28/2026		M			16,260	(3)	04/12/2033	Common Stock	16,260	$0	0	D

Explanation of Responses:

1. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.04 - $33.035 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.04 - $33.85 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

3. Reflects an award of stock options to purchase Common Shares that is fully vested.

Remarks:

	/s/ Tiago Girao, attorney-in-fact for Andrew J. Fromkin	05/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Immunovant (IMVT) director Andrew J. Fromkin report in this Form 4?

Andrew J. Fromkin reported exercising stock options and selling Immunovant common shares. He converted 196,601 options into stock, then sold 221,951 shares in open-market transactions, ending with 74,382 shares held directly after the reported activity.

How many Immunovant (IMVT) shares did the director sell and at what prices?

He sold 221,951 Immunovant common shares in open-market trades. Weighted average sale prices were about $32.64 and $33.56 per share, across multiple individual transactions within the price ranges disclosed in the Form 4 footnotes.

How many Immunovant (IMVT) stock options did Andrew J. Fromkin exercise?

He exercised stock options covering 196,601 shares of Immunovant common stock. The options had strike prices of $4.99, $7.94, $8.43, and $14.70 per share, and the filing notes that at least one option award was fully vested before exercise.

What is Andrew J. Fromkin’s Immunovant (IMVT) shareholding after these transactions?

Following the reported exercises and sales, Andrew J. Fromkin directly holds 74,382 Immunovant common shares. This reflects a net decrease in his direct share position while still leaving him with a meaningful ownership stake in the company.

Were the Immunovant (IMVT) share sales part of a Rule 10b5-1 trading plan?

The excerpted Form 4 footnotes describe weighted-average pricing for the sales but do not reference a Rule 10b5-1 trading plan. Based on the provided text, the transactions appear discretionary rather than explicitly pre-planned under such an arrangement.

What does the net effect of the Form 4 transactions mean for Immunovant (IMVT) insider ownership?

The director exercised options to acquire 196,601 shares, then sold 221,951 shares, resulting in a net reduction of his direct holdings to 74,382 shares. This reflects a routine net-sell pattern by an insider, not a change to total company share count.